CVS News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

CV

Mkt Cap

$113.62B

Volume

5.67M

Next Earnings

November 4th

Chart Financials Earnings News About Dividends Insider Filings

CVS Health (CVS) Stock Declines While Market Improves: Some Information for InvestorsCVS Health stock declined 1.4% to $87.60, underperforming the broader market which gained 1.49%. The stock has fallen 4.49% over the past month. The company is expected to report flat EPS of $1.6 for the upcoming quarter with revenue projected at $105.04 billion (up 2.11% YoY). CVS holds a Zacks Rank #3 (Hold) rating and trades at a Forward P/E of 11.07, below its industry average of 17.31.Zacks Investment Research · Sep 21, 2026

BTSG Faces $200M IRA Hit but Efficiency May Protect ProfitabilityBrightSpring Health Services' Home and Community Pharmacy segment experienced an 8% revenue decline to $540M in Q2, with the Inflation Reduction Act (IRA) accounting for approximately $50M of the impact. Despite a projected $200M revenue headwind in 2026 from IRA pricing changes, the company expects only a $15M EBITDA impact, demonstrating that operational efficiency gains from technology, automation, AI, and Lean initiatives are offsetting regulatory pressures. Peer companies Cardinal Health and CVS Health are similarly navigating IRA-driven revenue pressures while maintaining profitability through service agreements and operational improvements.Zacks Investment Research · Sep 17, 2026

Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure?Cardinal Health expects fiscal 2027 IRA pricing changes to create similar revenue headwinds as 2026, but management aims to preserve compensation and maintain profitability through distribution agreements and operational efficiency. Peers BrightSpring and CVS Health also face IRA-related revenue pressure but are offsetting impacts through operational improvements and specialty pharmacy growth.Zacks Investment Research · Sep 16, 2026

CVS Health (CVS) Suffers a Larger Drop Than the General Market: Key InsightsCVS Health closed down 1.17%, underperforming the S&P 500's 0.45% decline. Despite beating the Medical sector over the past month with a 1.64% gain, the company faces flat EPS projections for the upcoming quarter at $1.6, though full-year earnings are expected to grow 18.81%. CVS trades at a Forward P/E of 11.91, below its industry average, and holds a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Sep 15, 2026

Here's How CVS' Health Services Arm Is Positioned for Long-Term GrowthCVS Health's Health Services segment demonstrated strong Q2 2026 performance with revenues rising 11.5% to $51.8B and adjusted operating income climbing 10%. Health Care Delivery revenues jumped nearly 23% driven by Oak Street Health, while Pharmacy Services benefited from favorable drug mix and strong new sales of $6B. The company maintained its full-year 2026 outlook despite 340B program adjustments.Zacks Investment Research · Sep 15, 2026

Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellness Growth?CVS Health's Pharmacy & Consumer Wellness segment showed strong growth with operating income up 10.2% year-over-year to $1.48 billion in Q2 2026, supported by higher prescription volumes and improved margins. The company raised its 2026 operating income outlook for the segment by $220 million. CVS is expanding AI tools including Health100 and Claims Assist Manager to improve efficiency and customer service. However, reimbursement pressure, regulatory scrutiny, and insufficient Medicare Advantage payment updates remain key headwinds. With a discounted valuation (P/S of 0.29X vs. industry average 0.53X), Zacks recommends current holders maintain positions while prospective investors wait for a more favorable entry point.Zacks Investment Research · Sep 10, 2026

CVS Health (CVS) Up 1% Since Last Earnings Report: Can It Continue?CVS Health reported strong Q2 2026 results with adjusted EPS of $2.58 (up 42.5% YoY) and revenues of $106.10 billion (up 7.3%), beating consensus estimates. The company raised full-year 2026 guidance for earnings and revenues. However, estimates have trended downward over the past month with a -6.08% consensus shift, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.Zacks Investment Research · Sep 4, 2026

Here's How CVS' Improving Balance Sheet Supports DeleveragingCVS Health generated $10.6B in YTD operating cash flow and raised its full-year outlook to at least $11.5B, ending Q2 with $2.7B in cash. The company maintains a leverage ratio of 3.5x and expects improvement as it prioritizes balance-sheet strengthening over share buybacks in 2026-2027. Peers Align Technology and Cardinal Health also demonstrate strong liquidity positions with active capital deployment strategies.Zacks Investment Research · Sep 2, 2026

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?The iShares U.S. Healthcare Providers ETF (IHF) is a passively managed fund launched in 2006 that tracks the Dow Jones U.S. Select HealthCare Providers Index. With $1.25 billion in assets, a competitive 0.37% expense ratio, and a Zacks ETF Rank of 2 (Buy), it offers diversified exposure to healthcare providers. Year-to-date performance is up 20.18%, with a medium risk profile (beta of 0.72). Top holdings include UnitedHealth Group (20.61%), CVS Health, and Elevance Health.Zacks Investment Research · Sep 2, 2026

Why CVS Stock Rallied Tuesday MorningCVS Health stock rallied 3.4-3.7% on Tuesday following bullish commentary from Jefferies analyst Brian Tanquilut, who affirmed a buy rating with a $120 price target (28% upside). The analyst highlighted strong management guidance suggesting 2027 EPS of at least $8.44, upcoming share buybacks, and Aetna's successful turnaround with over $2 billion in year-over-year operating income growth. CVS has beaten expectations for four consecutive quarters and raised full-year guidance to $8.00 adjusted EPS (19% growth).The Motley Fool · Sep 1, 2026

CV

CVSCVS HEALTH CORPORATION

CVS

Pay with—

Available Balance0.00

Your PositionYou don't own any CVS yet.

Related Tickers

Earnings

Dividends

Last · Jul 23Quarterly

Amount$0.67

Yield3.03%

Annual$2.66